TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
San Diego, US
Size (employees)
118 (est)-10%
TearLab was founded in 2003 and is headquartered in San Diego, US

TearLab Office Locations

TearLab has office in San Diego
San Diego, US

TearLab Metrics

TearLab Summary

Market capitalization

$28.4 M

Closing share price

TearLab's current market capitalization is $28.4 M.

TearLab Financials

TearLab's revenue is $25.2 M in FY, 2015 which is 27.58% increase from the previous period.
FY, 2015FY, 2014FY, 2013


$25.2 M$19.7 M$14.6 M

Revenue growth, %


Gross profit

$12.6 M$10.9 M$6.5 M

Operating income

$-31.5 M$-25 M$-17.8 M

Operating expense total

$44.1 M$44.7 M$24.3 M

Net Income

$-33.2 M$-23.7 M$-29 M

Operating cash flow

$-2.5 M$-21.4 M$22.3 M

TearLab Market Value History

TearLab Online Presence

TearLab Company Life